PMID- 20085824
OWN - NLM
STAT- MEDLINE
DCOM- 20110104
LR  - 20100806
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Linking)
VI  - 6
IP  - 4
DP  - 2010 Aug
TI  - Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy 
      strategies.
PG  - 523-9
LID - 10.1016/j.nano.2010.01.001 [doi]
AB  - Dendritic cells (DCs) are potent antigen-presenting cells capable of initiating a 
      primary immune response and possess the ability to activate T cells and stimulate 
      the growth and differentiation of B cells. DCs provide a direct connection 
      between innate and adaptive immune response, and arise from bone marrow 
      precursors that are present in immature forms in peripheral tissues, where they 
      are prepared to capture antigens. DCs migrate from the peripheral tissues to the 
      closest lymph nodes through afferent lymphatic vessels to present the foreign 
      antigens, stimulating T-cell activation and initiating a cellular immune 
      response. Moreover, it is known that DCs have an important role in various 
      diseases and conditions involving the immune system, particularly in cancer and 
      autoimmune disorders. For these reasons, targeting nanoparticles (NPs) to DCs 
      provides a promising strategy for developing an efficient balanced and protective 
      immune response. NPs can modulate the immune response and might be potentially 
      useful as effective vaccine adjuvants for infectious disease and cancer therapy. 
      The objective of this review is to present the latest advances in NP delivery 
      methods targeting DCs, the mechanisms of action, potential effects, and 
      therapeutic results of these systems and their future applications, such as 
      improved vaccination strategies, cancer immunotherapy, and immunomodulatory 
      treatments. From the clinical editor: Dendritic cells (DCs) are potent 
      antigen-presenting cells capable of initiating a primary immune response and 
      activating T and B cells. The role of DC-s can be considered as a bridge between 
      innate and adaptive immunity. Targeting nanoparticles (NPs) to DCs can modulate 
      the immune response and might be useful as vaccine adjuvants in infectious 
      disease and cancer therapy.
CI  - 2010 Elsevier Inc. All rights reserved.
FAU - Klippstein, Rebecca
AU  - Klippstein R
AD  - CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine 
      (CSIC-University of Seville-UPO-Junta de Andalucia), Seville, Spain.
FAU - Pozo, David
AU  - Pozo D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100118
PL  - United States
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adjuvants, Immunologic/chemistry
MH  - Antigen-Presenting Cells/metabolism
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Immunotherapy/*methods
MH  - Nanoparticles/*chemistry
MH  - *Nanotechnology
MH  - Neoplasms/immunology/therapy
EDAT- 2010/01/21 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/01/21 06:00
PHST- 2009/10/01 00:00 [received]
PHST- 2009/12/29 00:00 [revised]
PHST- 2010/01/04 00:00 [accepted]
PHST- 2010/01/21 06:00 [entrez]
PHST- 2010/01/21 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
AID - S1549-9634(10)00008-0 [pii]
AID - 10.1016/j.nano.2010.01.001 [doi]
PST - ppublish
SO  - Nanomedicine. 2010 Aug;6(4):523-9. doi: 10.1016/j.nano.2010.01.001. Epub 2010 Jan 
      18.